Clinical Trials

40 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04938583 2023-10-17

Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

Phase 1/2 Unknown

54 enrolled

Ovarian Neoplasms

NCT03363867 2023-08-07

BEACON

30 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04201561 2023-06-26

SELENIUM

68 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peripheral Nervous System Diseases

NCT05819060 2023-04-19

The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab

44 enrolled

Ovarian Neoplasms

NCT01706120 2023-03-24

MITO16/MANGO-2

Phase 4 Unknown

400 enrolled

Ovarian Neoplasms

NCT01802749 2023-03-24

MITO16MANGO2b

406 enrolled

Ovarian Neoplasms

NCT05325229 2022-10-13

A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer

94 enrolled

Platinum-resistant Recurrent Ovarian Cancer

NCT04015739 2022-08-17

BOLD

74 enrolled

Carcinoma, Ovarian Epithelial, Recurrence

NCT05247619 2022-07-15

A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

49 enrolled

Uterine Cervical Neoplasms

NCT05444374 2022-07-05

A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer

48 enrolled

Uterine Cervical Neoplasms

NCT05158062 2022-04-26

Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer

35 enrolled

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT05310344 2022-04-04

Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer

50 enrolled

Ovarian Neoplasms

NCT05170594 2021-12-28

A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer

60 enrolled

Ovarian Neoplasms

NCT04974944 2021-10-01

First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer

172 enrolled

Uterine Cervical Neoplasms

NCT03462212 2021-08-27

MITO25

Phase 1/2 Unknown

290 enrolled

Fallopian Tube Neoplasms

NCT04679064 2021-08-27

NItCHE-MITO33

427 enrolled

Ovarian Neoplasms

NCT04973904 2021-07-22

Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer

35 enrolled

Uterine Cervical Neoplasms

NCT03912415 2020-09-18

FERMATA

316 enrolled

Uterine Cervical Neoplasms

NCT00652119 2020-08-19

Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin

Phase 1 Unknown

46 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03912402 2019-05-09

Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)

49 enrolled

Uterine Cervical Neoplasms

NCT03611179 2018-08-02

Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer

40 enrolled

Advanced Ovarian Cancer

NCT03095001 2017-04-13

Intraperitoneal Chemotherapy Alone or in Combination With Bevacizumab for Ovarian Cancer With Peritoneal Adhesion

70 enrolled

Ovarian Neoplasms

NCT01838538 2013-04-24

Clinical Study in Treatment of Malignant Ascites of Ovarian Cancer With Intraperitoneal Injection Bevacizumab Combined With Intraperitoneal Hyperthermic Perfusion Chemotherapy

54 enrolled

Ovarian Cancer With Malignant Ascites

NCT01770171 2013-01-17

MITOBEVAEND2

108 enrolled